TRANSCEND-T2D-2: Retatrutide vs Semaglutide

Study Overview

TRANSCEND-T2D-2 is a Phase 3, open-label, randomized, multicenter clinical trial comparing retatrutide head-to-head against semaglutide in adults with type 2 diabetes (T2D) inadequately controlled on metformin with or without an SGLT2 inhibitor. Registered as NCT06260722, the trial has enrolled approximately 1,200 participants and is evaluating the primary endpoint of change from baseline in HbA1c at 80 weeks.

This trial represents one of the most anticipated comparisons in the metabolic drug development landscape: the first direct head-to-head evaluation of a triple GIP/GLP-1/glucagon receptor agonist against the established GLP-1 RA standard of care in a diabetes population.

Why This Trial Matters

The First Head-to-Head Comparison

Prior to TRANSCEND-T2D-2, all clinical evidence for retatrutide came from placebo-controlled trials. While placebo comparisons establish efficacy, they do not answer the question that clinicians, payers, and patients most urgently need answered: Is retatrutide better than existing treatments?

Semaglutide (marketed as Ozempic for T2D) is the dominant GLP-1 receptor agonist in the diabetes market and has demonstrated robust glycemic control and cardiovascular benefits. Any new entrant must demonstrate superiority — or at minimum, differentiated value — to justify adoption.

TRANSCEND-T2D-2 provides this direct comparison for the first time.

Open-Label Design

The trial uses an open-label design, meaning both investigators and participants know which treatment they are receiving. This design choice is pragmatically necessary given the different injection devices, dose escalation protocols, and administration schedules of the two drugs. While open-label designs introduce potential bias in subjective endpoints, the primary endpoint (HbA1c) is an objective laboratory measurement that is not susceptible to reporting bias.

What Phase 2 Data Suggest

Retatrutide’s Phase 2 trial in type 2 diabetes (Jastreboff et al., NEJM 2023) provided strong glycemic efficacy signals that set expectations for the Phase 3 head-to-head:

• HbA1c reduction at 36 weeks: Up to -2.02% at the highest dose
• Mean baseline HbA1c: Approximately 8.3%
• Percentage achieving HbA1c under 7.0%: Up to 90% at the highest dose
• Percentage achieving HbA1c under 5.7% (normal range): Up to 46%
• Weight loss: Up to -16.9% at 36 weeks in the T2D population

For comparison, semaglutide 2.4 mg in the STEP-2 trial (diabetes population) achieved approximately -9.6% weight loss and HbA1c reductions of approximately -1.6% at 68 weeks. The Phase 2 retatrutide data at shorter duration already approached or exceeded these benchmarks.

However, cross-trial comparisons are inherently imprecise. TRANSCEND-T2D-2 eliminates this uncertainty by randomizing participants to the same protocol, the same visit schedule, and the same endpoints.

Trial Design

Key Inclusion Criteria (Expected)

Based on the trial registration and Eli Lilly’s Phase 3 program design:

• Adults with confirmed type 2 diabetes
• HbA1c within a specified range (typically 7.0-10.5%)
• Stable background therapy of metformin with or without SGLT2 inhibitor
• BMI above a specified threshold

Key Exclusion Criteria (Expected)

• Type 1 diabetes
• Recent cardiovascular events
• Significant renal impairment
• Current use of other GLP-1 RAs, insulin, or DPP-4 inhibitors

Expected Outcomes and Key Questions

Glycemic Superiority

The central question is whether retatrutide achieves statistically superior HbA1c reduction compared to semaglutide. Based on Phase 2 data, retatrutide’s triple receptor mechanism may produce greater glycemic improvement through:

• GLP-1 receptor activation: Glucose-dependent insulin secretion and glucagon suppression — the mechanism shared with semaglutide
• GIP receptor activation: Additional insulinotropic effects and potential beta-cell preservation
• Glucagon receptor activation: Paradoxically, controlled glucagon agonism in the context of GLP-1-mediated insulin secretion may improve hepatic glucose handling and metabolic flexibility

Weight Loss Differentiation

While HbA1c is the primary endpoint, weight loss will be a critical secondary outcome. Retatrutide’s Phase 2 weight loss in T2D (-16.9%) substantially exceeded semaglutide’s in comparable populations. If this differential holds in a head-to-head comparison, it strengthens retatrutide’s value proposition — particularly given that excess weight is a major driver of insulin resistance in T2D.

Safety Comparison

The open-label head-to-head design provides the first opportunity to compare adverse event profiles in the same trial:

• GI tolerability: Both drugs produce nausea, diarrhea, and vomiting. Whether retatrutide’s triple agonism produces a more or less tolerable GI profile than semaglutide’s GLP-1-only mechanism is unknown.
• Dysesthesia: The novel safety signal identified in TRIUMPH-4 (20.9% at 12 mg, 8.8% at 9 mg) has not been seen with semaglutide. This will be closely monitored.
• Cardiovascular parameters: Heart rate, blood pressure, and lipid changes will be tracked as secondary safety endpoints.

Implications for Clinical Practice

If TRANSCEND-T2D-2 demonstrates glycemic superiority with acceptable safety, it would position retatrutide as a potential first-line injectable for T2D — a market currently dominated by semaglutide. The results will directly inform:

• Treatment guidelines: Head-to-head superiority data are the gold standard for guideline recommendations
• Payer formulary decisions: Payers require comparative effectiveness data to justify coverage and positioning
• Patient selection: Understanding which patients benefit most from triple agonism versus single GLP-1 RA therapy

Timeline and Expected Results

The trial’s primary completion is expected in 2026, with results anticipated in late 2026 or early 2027. These data will be critical to Eli Lilly’s regulatory and commercial strategy for retatrutide in the T2D indication — complementing the TRIUMPH obesity data and the broader TRANSCEND diabetes program.

The 80-week duration provides a longer observation window than the 36-week Phase 2 trial, allowing assessment of durability of glycemic control and long-term tolerability.

Summary

TRANSCEND-T2D-2 is the first head-to-head comparison of retatrutide against an established GLP-1 receptor agonist (semaglutide) in type 2 diabetes. With 1,200 participants, an 80-week primary endpoint, and an open-label randomized design, this trial will provide the comparative effectiveness data that clinicians, payers, and guideline committees need to evaluate retatrutide’s place in T2D therapy. Phase 2 data suggest retatrutide may offer superior glycemic control and substantially greater weight loss, but the TRANSCEND-T2D-2 results will replace cross-trial estimates with direct evidence.